Vecuronium Bromide

Muscle relaxation is a core clinical requirement in surgical procedures to ensure airway management and reduce operational stress. Non-depolarizing muscle relaxants have become the mainstream choice due to their reversible effects and few adverse reactions. Vecuronium bromide is a monoquaternary ammonium steroidal non-depolarizing muscle relaxant. It competitively binds to the N2 cholinergic receptors on the motor endplate of skeletal muscle, blocks the depolarization effect of acetylcholine, and relaxes skeletal muscle. Its muscle relaxant potency is 1-1.5 times that of pancuronium bromide, and it has no obvious vagus nerve blocking or histamine releasing effects, making it particularly suitable for surgical patients with cardiovascular diseases, elderly patients, and people in intensive care units who require long-term muscle relaxation for assisted ventilation.

Driven by factors such as the recovery of global surgical volume and the popularization of ambulatory surgery in recent years, the market demand for vecuronium bromide has maintained sustained and steady growth. Data show that in 2023, the sales of vecuronium bromide preparations at the terminal of domestic public medical institutions exceeded 1.8 billion yuan, with a compound annual growth rate of 6.2% in the past three years. At present, generic drugs account for more than 92% of the domestic market, and leading manufacturers are concentrated in East China and Southwest China. Among them, vecuronium bromide for injection has been included in multiple batches of national centralized procurement, with an average price reduction of over 70% for winning bids. The stability of the API supply chain of the winning enterprises has become a core competitive factor, and there are currently fewer than 10 domestic enterprises with compliant API supply capacity.

The original developer of vecuronium bromide is Organon, with the original brand name "Norcuron". The core compound patents of vecuronium bromide expired in the United States and Europe in 2006, and the Chinese compound patent expired in 2008. The main dosage form approved for the original product is injection, with specifications of 4mg and 10mg. The original product has been included in the Chinese *Catalogue of Chemical Reference Preparations* and the FDA Reference Preparation Catalogue. Up to now, there are 14 valid registration numbers of vecuronium bromide on the domestic CDE API registration platform, among which 8 are in A status and can support associated declaration. More than 20 domestic enterprises have obtained approval for the marketing of vecuronium bromide for injection. (Data as of October 2024, please refer to the official website of CDE for the latest information)

CATO can provide a full set of vecuronium bromide impurity reference standards, covering synthesis process impurities, degradation impurities and isotopically labeled substances, which comply with the regulatory requirements of the Chinese Pharmacopoeia, FDA and other regulations. Most impurities are in stock, and orders for in-stock products placed before 16:00 can be shipped on the same day, which can fully meet the reference standard supply needs of pharmaceutical enterprises in the process of API R&D, quality research and consistency evaluation.